Fully human therapeutic monoclonal antibodies.

Weiner, Louis M

doi:10.1097/01.cji.0000192105.24583.83

Cited by 164Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsProtein purification and stability

Fully human therapeutic monoclonal antibodies.

Weiner, Louis M·2006·Journal of Immunotherapy

DOI 10.1097/01.cji.0000192105.24583.83

Open this paper in CoChat — free account

Abstract

Monoclonal antibody (mAb) therapy has been facilitated by a number of technologic advances over the past 30 years. Whereas hybridoma development of murine mAbs was requisite for the development of mAbs as drugs, the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clinical application of mAbs. Sensitization to mAb therapeutics poses significant risk to the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but did not eliminate the rodent content of mAbs; thus, immunogenicity remained a concern. Further elimination of rodent sequences enabled the production of humanized mAbs, followed by current technology using phage display and, finally, transgenic mice technology, which allows for the generation of fully human therapeutic mAbs. The reduced immunogenicity of this new generation of mAbs is expected to enhance efficacy, safety, and ease of use. In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues.

Integrity signals

Registry

Crossref · 10.1097/01.cji.0000192105.24583.83

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Denosumab and many other fully human therapeutic antibodies are produced in transgenic mice in which murine Ig genes have been deleted and replaced with human orthologs.
“Denosumab and numerous other fully human therapeutic antibodies have been made in transgenic mice, wherein their murine Ig genes have been deleted and replaced with human orthologs (431, 432).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [431]
A fully human anti-RANKL antibody has low potential for immune responses, an attribute borne out in clinical trials with denosumab.
“Another potential advantage of a fully human anti-RANKL antibody is the low potential for immune responses (431), a theoretical attribute that has been borne out in clinical trials with denosumab.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [431]

Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200 · see citing works
Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143 · see citing works
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427 · see citing works
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012 · see citing works
By-passing immunization
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. P. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,605 · see citing works
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,594 · see citing works
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562 · see citing works
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,509 · see citing works
The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function
McCune, J. M., Namikawa, R., Kaneshima, H., Shultz, L. D., Lieberman, M., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2971269 · Cited by 1,404 · see citing works
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,040 · see citing works
Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,028 · see citing works
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 632 · see citing works
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 623 · see citing works
Self-citation
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 554 · see citing works
Antibody framework residues affecting the conformation of the hypervariable loops
Foote, J., & Winter, G. P. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)91010-m · Cited by 525 · see citing works
Selection of phage antibodies by binding affinity
Hawkins, R. E., Russell, S. J., & Winter, G. P. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90639-2 · Cited by 522 · see citing works
The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus
Matsuda, F., Ishii, K., Bourvagnet, P., Kuma, K., Hayashida, H., Miyata, T., & Honjo, T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2151 · Cited by 401 · see citing works
Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
Mendez, M. J., Green, L. L., Corvalán, J. R. F., Jia, X., Maynard-Currie, C. E., Yang, X.-D., Gallo, M., Louie, D. M., Lee, D. V., Erickson, K. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-146 · Cited by 376 · see citing works
Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y. C., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355 · see citing works
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M., Dodd, S. W., Wood, J. F., Whitlow, M. D., Snoy, P. J., & Schlom, J. (1991) · PubMed · Cited by 338 · see citing works
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
Rowinsky, E. K., Schwartz, G. H., Gollob, J., Thompson, J. A., Vogelzang, N. J., Figlin, R. A., Bukowski, R. M., Haas, N. B., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329 · see citing works
IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION
Chatenoud, L., Ferran, C. J., Legendre, C. M., Thouard, I., Merite, S., REUTER, A. M., Gevaert, Y., Kreis, H., Franchimont, P., & Bach, J. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 319 · see citing works
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T. G., Hudson, D., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266 · see citing works
Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformation
Kettleborough, C. A., Saldanha, J. W., Heath, V. J., Morrison, C., & Bendig, M. M. (1991) · Protein Engineering Design and Selection · doi:10.1093/protein/4.7.773 · Cited by 198 · see citing works
Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review
Sgro, C. (1995) · Toxicology · doi:10.1016/0300-483x(95)03123-w · Cited by 170 · see citing works
Antibody engineering by codon-based mutagenesis in a filamentous phage vector system
Glaser, S., Yelton, D. E., & Huse, W. D. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.12.3903 · Cited by 112 · see citing works
Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., Wood, J. F., Hubert, S. L., & Schlom, J. (1993) · PubMed · Cited by 107 · see citing works
Clinical Reactions and Serologic Changes After the Administration of Heterologous Antilymphocyte Globulin to Human Recipients of Renal Homografts
Kashiwagi, N., Brantigan, C. O., BRETTSCHNEIDER, L., GROTH, C. G., & Starzl, T. E. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-2-275 · Cited by 95 · see citing works
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
Holliger, P., Brissinck, J., Williams, R. L., Thielemans, K., & Winter, G. P. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.3.299 · Cited by 94 · see citing works
Emil von Behring and serum therapy
Winau, F., & Winau, R. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(01)01526-x · Cited by 90 · see citing works
EVIDENCE THAT ANTIHUMAN TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY PREVENTS OKT3-INDUCED ACUTE SYNDROME
Charpentier, B., HIESSE, C., Lantz, O. J., Ferran, C. J., Stephens, S., OʼSHAUGNESSY, D., Bodmer, M., Benoît, G., Bach, J., & Chatenoud, L. (1992) · Transplantation · doi:10.1097/00007890-199212000-00011 · Cited by 78 · see citing works
Anaphylactic Shock after Retreatment with OKT3 Monoclonal Antibody
Abramowicz, D., Crusiaux, A., & Goldman, M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271018 · Cited by 71 · see citing works
Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production.
Jakobovits, A., Vergara, G. J., Kennedy, J. L., Hales, J. F., McGuinness, R., Casentini-Borocz, D., Brenner, D. G., & Otten, G. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2551 · Cited by 69 · see citing works
Severe anaphylactic reaction to infliximab
Stallmach, A., Giese, T., Schmidt, C., Meuer, S. C., & Zeuzem, S. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200406000-00018 · Cited by 47 · see citing works
A quantitative study of the binding of ALS to various cell types.
Skamene, E., & Russell, P. S. (1971) · PubMed · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · see citing works
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,366 · see citing works
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works
Recent advances in large-scale production of monoclonal antibodies and related proteins.
Shukla, A., & Thömmes, J. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.02.001 · Cited by 560 · see citing works
Panitumumab versus Cetuximab in Patients with Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473 · see citing works
Polymeric nanoparticles for cancer therapy
Parveen, S., & Sahoo, S. K. (2008) · Journal of drug targeting · doi:10.1080/10611860701794353 · Cited by 427 · see citing works
The pharmacology and therapeutic applications of monoclonal antibodies
Castelli, S., McGonigle, P., & Hornby, P. J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.535 · Cited by 371 · see citing works
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
Shealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., Vafa, O., Gunn, G. R., Tam, S. H., Sague, S. L., et al. (2010) · mAbs · doi:10.4161/mabs.12304 · Cited by 243 · see citing works
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237 · see citing works
Bioanalytical LC–MS/MS of protein-based biopharmaceuticals
van den Broek, I., Niessen, W. M. A., & van Dongen, W. D. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.04.030 · Cited by 231 · see citing works
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Dostálek, M., Gardner, I. B., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 231 · see citing works
Nanomedicine
Parveen, S., & Sahoo, S. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645100-00002 · Cited by 188 · see citing works
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 188 · see citing works
Therapeutic monoclonal antibodies in ophthalmology
Rodrigues, E. B., Farah, M. E., Maia, M., Penha, F. M., Regatieri, C. V., Melo, G. B., Pinheiro, M. M., & Zanetti, C. R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.005 · Cited by 173 · see citing works
In vivoapplications of magnetic nanoparticle hyperthermia
Hilger, I. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.832815 · Cited by 175 · see citing works
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
Cutsem, E. V., Siena, S., Humblet, Y., Canon, J.-L., Maurel, J., Bajetta, E., Neyns, B., Kotasek, D., Santoro, A., Scheithauer, W., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm399 · Cited by 155 · see citing works
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140 · see citing works
Clinical development of anti-RANKL therapy
Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 138 · see citing works
Improving the Oral Efficacy of Recombinant Granulocyte Colony-Stimulating Factor and Transferrin Fusion Protein by Spacer Optimization
Bai, Y., & Shen, W. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9059-5 · Cited by 135 · see citing works
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 131 · see citing works
Engineering antibodies for clinical applications
Jain, M., Kamal, N., & Batra, S. K. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.05.001 · Cited by 129 · see citing works
The biology of Ku and its potential oncogenic role in cancer
Gullo, C. A., Au, M., Ge, F., & Teoh, G. K. H. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.01.001 · Cited by 128 · see citing works
Antibody engineering and modification technologies
Filpula, D. R. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.03.004 · Cited by 124 · see citing works
Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy
Schirrmann, T., Meyer, T., Schütte, M., Frenzel, A., & Hust, M. (2011) · Molecules · doi:10.3390/molecules16010412 · Cited by 121 · see citing works
Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
Li, S., Kussie, P. H., & Ferguson, K. M. (2008) · Structure · doi:10.1016/j.str.2007.11.009 · Cited by 120 · see citing works
Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain
Schnitzer, T. J., Lane, N. E., Birbara, C. A., Smith, M. D., Simpson, S. L., & Brown, M. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.01.009 · Cited by 118 · see citing works
Absolute Quantification of Monoclonal Antibodies in Biofluids by Liquid Chromatography−Tandem Mass Spectrometry
Hagman, C., Ricke, D. O., Ewert, S., Bek, S., Falchetto, R. A., & Bitsch, F. (2008) · Analytical Chemistry · doi:10.1021/ac702115b · Cited by 115 · see citing works
Evolution and Emergence of Therapeutic Monoclonal Antibodies
Foltz, I. N., Karow, M. L., & Wasserman, S. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002033 · Cited by 99 · see citing works
The role of osteoprotegerin in cardiovascular disease
Montagnana, M., Lippi, G., Danese, E., & Guidi, G. C. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.727019 · Cited by 98 · see citing works
Panitumumab
Keating, G. M. (2010) · Drugs · doi:10.2165/11205090-000000000-00000 · Cited by 88 · see citing works
A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis
de Kruif, J., Bakker, A. B. H., Marissen, W. E., Kramer, R. A., Throsby, M., Rupprecht, C. E., & Goudsmit, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145053 · Cited by 85 · see citing works
A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use
Wagner, K. S., Stickings, P., White, J. M., Neal, S., Crowcroft, N. S., Sesardic, D., & Efstratiou, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.094 · Cited by 76 · see citing works
Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 74 · see citing works
Self-citation
Recombinant Antibodies and In Vitro Selection Technologies
Geyer, C. R., McCafferty, J., Dübel, S., Bradbury, A. M., & Sidhu, S. S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-931-0_2 · Cited by 73 · see citing works
Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody
Olafsen, T., Gu, Z., Sherman, M. A., Leyton, J. V., Witkosky, M. E., Shively, J. E., Raubitschek, A. A., Morrison, S. L., Wu, A. M., & Reiter, R. E. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318031b53b · Cited by 70 · see citing works
A Universal Strategy for Development of a Method for Absolute Quantification of Therapeutic Monoclonal Antibodies in Biological Matrices Using Differential Dimethyl Labeling Coupled with Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry
Ji, C., Sadagopan, N., Zhang, Y., & Lepsy, C. S. (2009) · Analytical Chemistry · doi:10.1021/ac901800f · Cited by 65 · see citing works
Mining human antibody repertoires
Beerli, R. R., & Rader, C. M. (2010) · mAbs · doi:10.4161/mabs.12187 · Cited by 57 · see citing works
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 55 · see citing works
Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer
Pedretti, M., Soltermann, A., Arni, S., Weder, W., Neri, D., & Hillinger, S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.07.013 · Cited by 55 · see citing works
Mucosal injury from targeted anti-cancer therapy
Keefe, D. M. K., & Gibson, R. J. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0181-z · Cited by 54 · see citing works
The present state of the art in expression, production and characterization of monoclonal antibodies
Gaughan, C. L. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9625-z · Cited by 53 · see citing works
Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies
Pedretti, M., Rančić, Z., Soltermann, A., Herzog, B. A., Schliemann, C., Lachat, M. L., Neri, D., & Kaufmann, P. A. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.07.043 · Cited by 52 · see citing works
Masked Selection: A Straightforward and Flexible Approach for the Selection of Binders Against Specific Epitopes and Differentially Expressed Proteins by Phage Display
Even-Desrumeaux, K., Névoltris, D., Lavaut, M. N., Alim, K., Borg, J., Audebert, S., Kerfélec, B., Baty, D., & Chames, P. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.025486 · Cited by 55 · see citing works
Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody
Apgar, J. R., Mader, M., Agostinelli, R., Benard, S., Bialek, P., Johnson, M., Gao, Y., Krebs, M. R. H., Owens, J. M., Parris, K. D., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1215786 · Cited by 52 · see citing works
Pharmacokinetics and Safety Profile of the Human Anti- Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers
Lazar, H., Horn, M. P., Zuercher, A. W., Imboden, M. A., Durrer, P., Seiberling, M., Pokorny, R., Hammer, C., & Lang, A. B. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01699-08 · Cited by 52 · see citing works
Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study.
Lyer, S., Tietze, R., Jurgons, R., Struffert, T., Engelhorn, T., Schreiber, E., Dörfler, A., & Alexiou, C. (2010) · PubMed · Cited by 49 · see citing works
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 48 · see citing works
Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy
Wu, J., Schultz, J. S., Weldon, C. L., Sule, S. V., Chai, Q., Geng, S. B., Dickinson, C. D., & Tessier, P. M. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv045 · Cited by 48 · see citing works
Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma
Lamoureux, F., Picarda, G. G. A., Rousseau, J., Gourden, C., Battaglia, S., Charrier, C., Pitard, B., Heymann, D., & Rédiní, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0497 · Cited by 47 · see citing works
Monoclonal antibody purification and its progression to commercial scale
Chahar, D. S., Ravindran, S., & Pisal, S. S. (2019) · Biologicals · doi:10.1016/j.biologicals.2019.09.007 · Cited by 45 · see citing works
Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections
Seixas, A. M. M., Sousa, S. A., & Leitão, J. H. (2022) · Vaccines · doi:10.3390/vaccines10111789 · Cited by 44 · see citing works
Recombinant plasma proteins
Burnouf, T. P. R. (2010) · Vox Sanguinis · doi:10.1111/j.1423-0410.2010.01384.x · Cited by 45 · see citing works
An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors
Stephenson, J., Gregory, C., Burris, H. A., Larson, T., Verma, U. N., Cohn, A. L., Crawford, J., Cohen, R. B., Martin, J., Lum, P., et al. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.005 · Cited by 43 · see citing works
Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review
Suh, K., Kyei, I., & Hage, D. S. (2022) · Journal of Separation Science · doi:10.1002/jssc.202200112 · Cited by 41 · see citing works
Research and development of therapeutic mAbs: An analysis based on pipeline projects
Geng, X., Kong, X., Hu, H., Chen, J., Yang, F. Q., Liang, H., Chen, X., & Yuanjia, H. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1074362 · Cited by 41 · see citing works
Bacteriophages in health and disease
Hyman, P., & Abedon, S. T. (2012) · CABI eBooks · doi:10.1079/9781845939847.0000 · Cited by 40 · see citing works
Top-Down Lc–Ms Quantitation of Intact Denatured and Native Monoclonal Antibodies in Biological Samples
Zhang, L., Vasicek, L. A., Hsieh, S., Zhang, S., Bateman, K. P., & Henion, J. D. (2018) · Bioanalysis · doi:10.4155/bio-2017-0282 · Cited by 40 · see citing works
Pros and Cons of the Immunogenicity of Monoclonal Antibodies in Cancer Treatment: A Lesson from Autoimmune Diseases
Talotta, R., Rucci, F., Canti, G. L., & Scaglione, F. (2019) · Immunotherapy · doi:10.2217/imt-2018-0081 · Cited by 40 · see citing works
Current status and perspectives of biopharmaceutical drugs
Ryu, J. K., Kim, H. S., & Nam, D. H. (2012) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-012-0095-1 · Cited by 39 · see citing works
A sensitive amperometric immunosensor for the detection of carcinoembryonic antigen using ZnMn2O4@reduced graphene oxide composites as signal amplifier
Fan, X., Deng, D., Chen, Z., Qi, J., Li, Y., Han, B., Huan, K., & Luo, L. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.129852 · Cited by 36 · see citing works
Panitumumab
Hoy, S. M., & Wagstaff, A. J. (2006) · Drugs · doi:10.2165/00003495-200666150-00011 · Cited by 35 · see citing works
Codon engineering for improved antibody expression in mammalian cells
Carton, J. M., Sauerwald, T. M., Hawley‐Nelson, P., Morse, B. A., Peffer, N. J., Beck, H., Lu, J., Cotty, A., Amegadzie, B. Y., & Sweet, R. (2007) · Protein Expression and Purification · doi:10.1016/j.pep.2007.05.017 · Cited by 34 · see citing works
Frontier of therapeutic antibody discovery: The challenges and how to face them
Lu, Z. (2012) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v3.i12.187 · Cited by 30 · see citing works
Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review
Azevedo, R., Ferreira, J. A., Peixoto, A., Neves, M., Sousa, N., Lima, Á., & Santos, L. L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.002 · Cited by 30 · see citing works
Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
Stamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 30 · see citing works
Membrane‐tethered proteins for basic research, imaging, and therapy
Cheng, T., & Roffler, S. R. (2008) · Medicinal Research Reviews · doi:10.1002/med.20127 · Cited by 28 · see citing works
Use of Generic LC–MS/MS Assays to Characterize Atypical PK Profile of A Biotherapeutic Monoclonal Antibody
Law, W. S., Genin, J., Miess, C., Tréton, G., Warren, A. P., Lloyd, P. M., Dudal, S., & Krantz, C. (2014) · Bioanalysis · doi:10.4155/bio.14.167 · Cited by 26 · see citing works
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 26 · see citing works
Immunogenicity of panitumumab in combination chemotherapy clinical trials
Weeraratne, D. K., Chen, A., Pennucci, J. J., Wu, C., Zhang, K., Wright, J., Ruixo, J. J. P., Yang, B., Kaliyaperumal, A., Gupta, S., et al. (2011) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-11-17 · Cited by 26 · see citing works
In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
Muñoz, R., Arias, Y., Ferreras, J. M., Jiménez, P., Langa, C., Rojo, M. A., Gayoso, M. J., Córdoba-Díaz, D., Bernabéu, C., & Girbés, T. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1357-7 · Cited by 25 · see citing works
Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3
Pfaffen, S., Hemmerle, T., Weber, M., & Neri, D. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.11.004 · Cited by 25 · see citing works
Antibody Phage Display
Hust, M., Thie, H., Schirrmann, T., & Dübel, S. (2009) · doi:10.1002/9780470485408.ch8 · Cited by 25 · see citing works
Stable Supply of Large Amounts of Human Fab from the Inclusion Bodies in E. coli
Fujii, T., Ohkuri, T., Onodera, R., & Ueda, T. (2007) · The Journal of Biochemistry · doi:10.1093/jb/mvm075 · Cited by 24 · see citing works
The role and efficacy of denosumab in the treatment of osteoporosis: an update
Charopoulos, I. N., Orme, S. M., & Giannoudis, P. V. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.516249 · Cited by 24 · see citing works
Technological advances in mucositis research: New insights and new issues
Gibson, R. J., Bowen, J. M., & Keefe, D. M. K. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.02.001 · Cited by 23 · see citing works
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor
Rolfo, C. D., Raez, L. E., Russo, A. G., Reguart, N., Campelo, R. G., Bronte, G., Papadimitriou, K., & Silvestris, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.843667 · Cited by 22 · see citing works
Opportunities and Challenges for Antibodies against Intracellular Antigens
Yang, X., Xie, S., Yang, X., Jumbo, J. C. C., Hou, X., Tang, Z., Yao, H., Mo, F., Yin, S., Liu, A., et al. (2019) · Theranostics · doi:10.7150/thno.35486 · Cited by 22 · see citing works
Miniaturized single-cell technologies for monoclonal antibody discovery
Lent, J. V., Breukers, J., Ven, K., Ampofo, L., Horta, S., Pollet, F., Imbrechts, M., Geukens, N., Vanhoorelbeke, K., Declerck, P. J., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00243k · Cited by 22 · see citing works
Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies
Lee, S. C., López‐Albaitero, A., & Ferris, R. L. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0023-5 · Cited by 21 · see citing works
Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display
Frenzel, A., Fröde, D., Meyer, T., Schirrmann, T., & Hust, M. (2012) · Current Biotechnology · doi:10.2174/2211550111201010033 · Cited by 19 · see citing works
Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors
Kast, J., Dutta, S., & Upreti, V. V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01809-4 · Cited by 18 · see citing works
Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study
Cong, Y., Zhang, Z., Zhang, S., Hu, L., & Gu, J. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500098 · Cited by 17 · see citing works
Inhibition of osteoclastogenesis by RNA interference targeting RANK
Ma, R., Xu, J., Dong, B., Kauther, M. D., Jäger, M., & Wedemeyer, C. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-154 · Cited by 15 · see citing works
Downregulation of Peroxiredoxin I by a Novel Fully Human Phage Display Recombinant Antibody Induces Apoptosis and Enhances Radiation Sensitization in A549 Lung Carcinoma Cells
Guo, Q., Huang, X., Zhang, J., Luo, Y., Peng, Z., & Li, S. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.0989 · Cited by 14 · see citing works
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA
Sgier, D., Zuberbuehler, K., Pfaffen, S., & Neri, D. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp089 · Cited by 14 · see citing works
Monoclonal Antibodies: From Structure to Therapeutic Application
Davis, J. D., Deng, R., Boswell, C. A., Zhang, Y., Li, J., Fielder, P. J., Joshi, A., & Kenkare-Mitra, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_7 · Cited by 14 · see citing works
Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Bahrami, S., Kazemi, B., Zali, H., Black, P. C., Basiri, A., Bandehpour, M., Hedayati, M., & Sahebkar, A. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666191016124935 · Cited by 13 · see citing works
Therapeutic Recombinant Monoclonal Antibodies
Bakhtiar, R. (2012) · Journal of Chemical Education · doi:10.1021/ed200392h · Cited by 12 · see citing works
EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Kanwar, S. S., Nautiyal, J., & Majumdar, A. P. N. (2010) · Current Drug Targets · doi:10.2174/138945010791170851 · Cited by 12 · see citing works
Biologic Therapy
Eisenberg, S. (2012) · Journal of Infusion Nursing · doi:10.1097/nan.0b013e31826579aa · Cited by 11 · see citing works
Denosumab for the Management of Postmenopausal Osteoporosis
Singer, A. J., & Grauer, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2235 · Cited by 11 · see citing works
New Trends in Epidermal Growth Factor Receptor-Directed Monoclonal Antibodies
Markman, B., Capdevila, J., Élez, E., & Tabernero, J. M. (2009) · Immunotherapy · doi:10.2217/imt.09.66 · Cited by 10 · see citing works
Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars
van de Weert, M., & Møller, E. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-75841-1_5 · Cited by 10 · see citing works
Qualification and application of a liquid chromatography–quadrupole time‐of‐flight mass spectrometric method for the determination of trastuzumab in rat plasma
Park, M., Lee, M., & Shin, Y. G. (2015) · Biomedical Chromatography · doi:10.1002/bmc.3606 · Cited by 9 · see citing works
Cattle-derived knob paratopes grafted onto peripheral loops of the IgG1 Fc region enable the generation of a novel symmetric bispecific antibody format
Yanakieva, D., Vollmer, L., Evers, A., Siegmund, V., Arras, P., Pekar, L., Doerner, A., Valldorf, B., Kolmar, H., Zielonka, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1238313 · Cited by 8 · see citing works
Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen
Dong, L., Masaki, Y., Takegami, T., Kawanami, T., Itoh, K., Jin, Z., Huang, C.-R., Tong, X., Fukushima, T., Tanaka, M., et al. (2007) · International Immunology · doi:10.1093/intimm/dxl150 · Cited by 8 · see citing works
History of monoclonal antibodies and lessons for the development of stem cell therapeutics
Vertès, A. A., & Dowden, N. J. (2015) · doi:10.1002/9781118846193.ch33 · Cited by 8 · see citing works
Development and evaluation of a novel anti-colorectal cancer monoclonal antibody, WL5
Liu, J., Di, G., Wu, C.-T., Hu, X., & Duan, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.089 · Cited by 7 · see citing works
Nanomedicine: Drug Delivery Systems and Nanoparticle Targeting
윤혜원, 강건욱, 정준기, & 이동수 (2008) · Nuclear Medicine and Molecular Imaging · Cited by 7 · see citing works
Genetic Engineering Antibody: Principles and Application
Zhao, L., Wu, Q., Song, R., & Yun, Z. (2019) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/612/2/022045 · Cited by 7 · see citing works

Authors: Weiner, L. M.
Affiliations: Fox Chase Cancer Center (US)
Corresponding author: Weiner, Louis M
ORCID: Weiner, Louis M
Venue: Journal of Immunotherapy
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2006-01
Volume: 29
Issue: 1
Pages: 1-9
ISSN: 1524-9557 (ISSN-L)
DOI: 10.1097/01.cji.0000192105.24583.83
OpenAlex: W1971456299
Cited by: 164
References: 36
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 17
FWCI: 2.09
Type: journal article
Language: en
Open access: closed
Locations: Journal of Immunotherapy (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 50633, CA06926, R01CA050633)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords: monoclonal antibodies, fully human antibodies, immunogenicity, chimeric antibodies, humanized monoclonal antibody, transgenic mice, phage display, hybridoma technology, antibody engineering, therapeutic antibodies
MeSH terms: Animals, Antibodies, Monoclonal, Genetic Engineering, Humans, Mice, Transgenic, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fully human therapeutic monoclonal antibodies.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks